Jacobs Levy Equity Management’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Jacobs Levy Equity Management’s Portfolio HARP Stock Details HARP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-32,984	Closed	-$630K	–	1214
2022 Q2	$630K	Sell	32,984 -4,226	-11%	-$109K	﹤0.01%	832
2022 Q1	$1.85M	Buy	37,210 +4,529	+14%	+$235K	0.01%	640
2021 Q4	$2.47M	Buy	32,681 +23,971	+275%	+$1.64M	0.02%	576
2021 Q3	$688K	Buy	+8,710	New	+$876K	﹤0.01%	820
2021 Q1	–	Sell	-6,439	Closed	-$1.07M	–	1145
2020 Q4	$1.07M	Sell	6,439 -384	-6%	-$59.3K	0.01%	705
2020 Q3	$1.16M	Buy	6,823 +1,186	+21%	+$171K	0.01%	631
2020 Q2	$936K	Buy	5,637 +2,702	+92%	+$422K	0.01%	680
2020 Q1	$340K	Buy	+2,935	New	+$413K	﹤0.01%	811

Other funds holding HARP

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PSC

Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return

Jacobs Levy Equity Management's HARP Position: Q3 2022 in Review

Jacobs Levy Equity Management sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q3 2022, closing a stake of 32,984 shares — an estimated $630K sold.

Jacobs Levy Equity Management first reported a position in HARP in Q1 2020 and held it in 8 quarters. The position peaked at $2.47M in Q4 2021. 52 funds tracked by Wall St. Rank hold HARP as of Q3 2022.

Jacobs Levy Equity Management reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 32,984 Harpoon Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $630K.
Jacobs Levy Equity Management first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2020 and held it in 8 quarters.
Jacobs Levy Equity Management's Harpoon Therapeutics, Inc. Common Stock position peaked at $2.47M in Q4 2021.
52 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2022, filed 15 Nov 2022.